Skip to main content
Lepu Biopharma Co., Ltd. logo

Lepu Biopharma Co., Ltd. — Investor Relations & Filings

Ticker · 2157 ISIN · CNE100004SM4 HKEX Manufacturing
Open in API
Filings indexed 239 across all filing types
Latest filing 2025-10-02 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2157

About Lepu Biopharma Co., Ltd.

http://www.lepubiopharma.com

Lepu Biopharma Co., Ltd. is an innovation-driven biopharmaceutical company dedicated exclusively to the research and development of oncology therapeutics. The company focuses on advanced tumor treatment modalities, including targeted therapy and cancer immunotherapy. Its strategically built product pipeline encompasses a range of candidate drugs, notably Antibody-Drug Conjugates (ADCs), immunotherapies, and oncolytic virus drugs, with assets spanning clinical and preclinical development stages. Lepu Biopharma leverages its proprietary ADC technology platform to drive the development of innovative treatments. The company pursues domestic commercialization through dedicated sales infrastructure while actively seeking global market access, particularly in the US and European markets, via strategic partnerships and out-licensing agreements for its drug candidates.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2025
Regulatory Filings Classification · 72% confidence The document is titled “Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules,” covering movements in authorised, issued, and treasury shares, plus confirmations. It is a standard periodic compliance return filed to the Hong Kong Exchange, not an earnings release, management report, or specific share issue notice. It does not announce a discrete capital change event but provides regulatory reporting of monthly movements. Therefore, it falls under the general “Regulatory Filings” category.
2025-10-02 English
2025 Interim Report
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled '2025 INTERIM REPORT' for Lepu Biopharma Co., Ltd. It contains comprehensive financial statements (Statement of Profit or Loss, Financial Position, Cash Flows), management discussion and analysis, and notes to the financial information for the six-month period ending June 30, 2025. It meets the criteria for an Interim/Quarterly Report as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H1 2025
2025-09-19 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2025
Regulatory Filings Classification · 87% confidence The document is a recurring monthly submission (Form FF301) to the Hong Kong Exchange listing office, summarizing movements in authorized share capital and issued/treasury shares under Chapter 19B of the Listing Rules. It is not an annual or quarterly financial report, not an earnings release, not a board/management change, nor a one‐off share issue or buyback announcement, but a regulatory filing required by the Exchange. It does not fall under any of the more specific categories, therefore it is classified under the general Regulatory Filings (RNS) category.
2025-09-04 English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025'. It contains detailed financial highlights, business review, management discussion and analysis (MDA), and a product pipeline summary for the interim period. It is a comprehensive report of financial performance for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H2 2025
2025-08-20 English
NOTICE OF BOARD MEETING
Regulatory Filings Classification · 64% confidence The document is a public announcement filed on the Hong Kong Exchange stating a notice of a Board meeting to consider and approve the interim results and any interim dividend recommendation. It is not the interim report itself, nor is it announcing a shareholder meeting or proxy solicitation. It does not fit into any specific category like Annual Report, Interim Report, Dividend Notice, Management Change, or Proxy Statement. Therefore, it falls into the fallback category of a general regulatory announcement (RNS).
2025-08-06 English
POSITIVE PROFIT ALERT
Earnings Release Classification · 78% confidence The document is a profit alert announcement under Hong Kong Listing Rule 13.09(2)(a), providing preliminary, unaudited key financial results for the six‐month period (a periodical update). It contains estimated profit figures and highlights only, similar to an earnings release rather than a full interim report or attachment notice. Therefore, it best fits the Earnings Release category (ER). H1 2025
2025-08-06 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.